Company intelligence / Profile preview

Yas Holding

Abu Dhabi, Abu Dhabi, United Arab Emirates

Ownership: Private
Employees: ~7000
Development stage: Other

Overview

Yas Holding has divested its main biopharma and IV manufacturing assets to Mubadala/KELIX bio as of October 2024, marking a strategic shift from direct manufacturing to broader healthcare investment and management.

Therapeutic areas: ImmunologyOncologyHematology
Modalities: Monoclonal antibodyFusion proteinSmall molecule
Industry: Investors

Partnerships

Alvotech (biosimilars)Alvogen (targeted generics licensing/distribution in MENA region)

Beyond the preview

Go deeper on Yas Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yas Holding.

Explore the full profile